Skip to content

A phase I dose finding study of oral TNO155 in adult patients with advanced solid tumors

Status
Completed
Phases
Phase 1
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2023-508925-29-00
Acronym
CTNO155X2101
Enrollment
113
Registered
2024-04-10
Start date
2017-06-29
Completion date
2025-07-04
Last updated
2025-02-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced solid tumors

Interventions

None listed

Sponsors

Novartis Pharma AG, Novartis Pharma AG
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Countries

Italy, Netherlands, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026